Full history for every metric is available with a Kvantra account
Avid Bioservices, Inc. (CDMO)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 54 | 60 | 96 | 120 | 149 | 140 | 150 |
| Operating profit | $m | -19 | -20 | |||||
| Net profit | $m | -4 | -7 | 11 | 128 | 1 | -141 | -152 |
| EPS reported | $ | -2.23 | -2.39 | |||||
| Operating cashflow per share | $ | 0.17 | 0.17 | |||||
| Capex per share | $ | 0.50 | 0.50 | |||||
| FCF per share | $ | -0.33 | -0.33 | |||||
| Free cash flow | $m | -21 | 0 | |||||
| Net debt | $m | 117 | 121 | |||||
| Book value equity | $m | 61 | 45 | |||||
| Book value per share | $ | 0.96 | 0.70 | |||||
| Number of shares | m | 63.2 | 63.84 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 7.92 | 17.83 | |||||
| P/S LTM | x | 3.45 | 5.31 | |||||
| P/FCF LTM | x | -23.12 | 5,088.55 | |||||
| EV/EBITDA LTM | x | -56.78 | -64.62 | |||||
| EV/Sales LTM | x | 4.66 | 6.11 | |||||
| Earnings Yield LTM | % | -29.19% | -17.83% | |||||
| FCF Yield | % | -4.32% | 0.02% | |||||
| Quality | ||||||||
| ROE | % | -231.16% | -112.44% | |||||
| ROIC | % | -6.95% | -6.95% | |||||
| Operating margin | % | -13.35% | -13.35% | |||||
| Gross margin | % | 5.23% | 5.23% | |||||
| FCF/Sales | % | -14.90% | -14.90% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -6.27% | +6.75% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.10 | 0.00 | |||||
| Net Debt/EBITDA | x | -14.78 | -14.78 | |||||
| EBIT/Net interest | x | -4.31 | -4.31 | |||||
| Net debt/market cap | % | 24.25% | 15.11% | |||||
| Net debt/Equity | x | 1.92 | 2.69 | |||||
| Gross debt/equity | x | 3.41 | 4.59 | |||||
Company overview
Avid Bioservices, Inc. operates as a Contract Development and Manufacturing Organization (CDMO), specializing in the development and CGMP-compliant production of biopharmaceutical drug substances. Their core expertise lies in compounds derived from mammalian cell culture, providing both clinical and commercial scale manufacturing solutions. The company is proficient in producing critical therapeutics such as monoclonal antibodies and recombinant proteins. Beyond manufacturing, their comprehensive service portfolio encompasses CGMP manufacturing for drug substances, bulk packaging, rigorous release and stability testing, and essential regulatory submission and support. Additionally, Avid Bioservices offers a range of process development services, including the optimization of upstream and downstream processes, alongside the development, testing, and characterization of analytical methods. Avid Bioservices primarily serves clients within the biotechnology and biopharmaceutical industries. The company, which was originally incorporated in 1981, was known as Peregrine Pharmaceuticals, Inc. before officially rebranding to Avid Bioservices, Inc. in January 2018. Its corporate headquarters are situated in Tustin, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Avid Bioservices, Inc. (CDMO)
Avid Bioservices, Inc. operates as a Contract Development and Manufacturing Organization (CDMO), specializing in the development and CGMP-compliant production of biopharmaceutical drug substances. Their core expertise lies in compounds derived from mammalian cell culture, providing both clinical and commercial scale manufacturing solutions. The company is proficient in producing critical therapeutics such as monoclonal antibodies and recombinant proteins. Beyond manufacturing, their comprehensive service portfolio encompasses CGMP manufacturing for drug substances, bulk packaging, rigorous release and stability testing, and essential regulatory submission and support. Additionally, Avid Bioservices offers a range of process development services, including the optimization of upstream and downstream processes, alongside the development, testing, and characterization of analytical methods. Avid Bioservices primarily serves clients within the biotechnology and biopharmaceutical industries. The company, which was originally incorporated in 1981, was known as Peregrine Pharmaceuticals, Inc. before officially rebranding to Avid Bioservices, Inc. in January 2018. Its corporate headquarters are situated in Tustin, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free